Description: Entinostat (MS-275) is an HDAC class I selective inhibitor of HDAC1, HDAC2 and HDAC3 (IC50=243/453/248 nM) with oral activity. Entinostat has antitumor activity. Target: Apoptosis, HDAC, Autophagy. Smiles: Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1. References: Beckers T, et al. Distinct...

MS-275 is an inhibitor of histone deacetylases (HDACs) that preferentially inhibits HDAC1 (IC50 = 300 nM) over HDAC3 (IC50 = 8 µM). However, it does not inhibit HDAC8 (IC50 > 100 µM). MS-275 induces cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1), slowing cell growth, differentiation, and tumor development in...

HDAC 1 inhibitor, Antitumor compound, Antiproliferative, TGF-beta type II receptor inducer, Apoptosis inducer, Anti-inflammatory, Angiogenesis inhibitor, Review.

MS-275 is a synthetic benzamide derivative that inhibited partially purified human histone deacetylase (HDA) with an IC50 of 2uM and induced hyperacetylation of nuclear histones in tumor cell lines. MS-275 inhibited the proliferation of various human tumor cell lines such as A2780, Calu-3, HL-60, and K562 (IC50...

A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription.